Skip to content

More Treatment Options, Better Patient Outcomes

June 13, 2020 / Arfinn Med MD /

More Treatment Options, Better Patient Outcomes

As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment.  In fact, a recent study from Columbia University’s Irving Medical Center found that,

“States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs”.

These findings highlight the importance of providing patients with options, especially when treating pain, that consider the negative effects of ‘industry norm’ medications. Our de-identified data in Arfinn Med of patients using cannabis to treat pain finds similar outcomes mentioned in the research:

A picture containing object, clock, meter Description automatically generated

If you are someone interested in learning more about medical marijuana, make sure to speak to your doctor about the potential benefits and risks associated with it.  If your doctor is unsure about its use and efficacies, make sure they register for Arfinn Med so they can query a database of de-identified data, opt-in to more rigorous patient monitoring tools, and track patient efficacies and treatment pathways through our electronic medical record system.      

Stories you may be interested in

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More →

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More →

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical…
Read More →

Florida doctors face new rules for medical marijuana (And how Arfinn Med can help)

TALLAHASSEE, Fla. – New rules laying out the do’s and don’ts physicians must follow when certifying patients to smoke medical marijuana took effect last week, but it’s not clear that doctors or patients are fully aware of them. Patients certified or recertified to smoke medical marijuana must sign a new standardized consent form as of last…
Read More →

COVID-19 and medical cannabis patients: What you need to know

In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More →

After marijuana edibles helped dying Holocaust survivor battle Alzheimer’s, his family’s foundation pushes for more research

A Massachusetts family’s experience giving marijuana edibles to their dying patriarch is set to kick off a desperately needed investigation into how cannabis might treat some of the more troubling symptoms of Alzheimer’s disease, a condition that affects 5.7 million Americans. Read the full story here.
Read More →

Leave a Comment

You must be logged in to post a comment.